Dahlia’s user-friendly interface provides easy access to study-related updates, messages, payment updates (if applicable), and other important activities.

Enhance your study experience with one simple app:
- Access treatment plans, appointments, and study information
- Add support users and request community assistance
- Receive convenient messages directly from the site
- Access payment information
- Set vacation reminders to remember your device

Stay engaged with your study using Dahlia.
*This app is for clinical participants only.*

- The human subject research conducted in our app has been approved by an institutional review board -- see attached document “XXX”

- Research subjects sign an informed consent document that covers the nature of research, procedures, confidentiality, point of contact and withdrawal process. Only patients that have been screened through a research site, have signed the approved ICF and are enrolled into the study are invited to use the app.

- The study sponsor, Formycon, has entered into a contract and Software License Agreement with StudyKIK to utilize the Dahlia app for the purposes of this study.

- This study is a randomized, double-blind, multicenter, pharmacokinetic equivalence clinical trial of adjuvant FYB206 (Keytruda biosimilar candidate) in comparison with Keytruda (Pembrolizumab) to demonstrate pharmacokinetic similarity in patients with completely resected stage iib/iic or stage iii melanoma (DAHLIA).